Health Care [ 4/12 ] | Biotechnology [ 20/74 ]
NASDAQ | Common Stock
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer.
The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer.
Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors.
The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells.
Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 22, 25 | -0.82 Increased by 0.00% | -0.69 Decreased by -18.84% |
| Feb 6, 25 | -0.79 Decreased by -2.60% | -0.72 Decreased by -9.72% |
| Nov 5, 24 | -0.68 Increased by +24.97% | -0.77 Increased by +12.30% |
| Aug 8, 24 | -0.78 Decreased by -4.00% | -0.85 Increased by +8.24% |
| May 16, 24 | -0.82 Decreased by -10.81% | -0.79 Decreased by -3.80% |
| Feb 8, 24 | -0.77 Decreased by -11.59% | -0.93 Increased by +17.20% |
| Nov 7, 23 | -0.90 Decreased by -13.92% | -0.86 Decreased by -4.65% |
| Aug 3, 23 | -0.75 Increased by +3.85% | -0.84 Increased by +10.71% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | N/A Decreased by -100.00% | -74.13 M Decreased by -34.60% | - - |
| Dec 31, 24 | 0.00 Decreased by N/A% | -66.34 M Decreased by -29.77% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -53.05 M Increased by +11.64% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -53.77 M Decreased by -8.51% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 4.04 M Increased by +N/A% | -55.08 M Decreased by -11.85% | Decreased by -1.36 K% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -51.12 M Decreased by -28.80% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -60.04 M Decreased by -39.31% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -49.55 M Decreased by -17.28% | Decreased by N/A% Decreased by N/A% |